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Objective To determine risk-reducing early salpingectomy and
delayed oophorectomy (RRESDO) acceptability and effect of
surgical prevention on menopausal sequelae/satisfaction/regret in
women at increased ovarian cancer (OC) risk.
Design Multicentre, cohort, questionnaire study
(IRSCTN:12310993).
Setting United Kingdom (UK).
Population UK women without OC ≥18 years, at increased OC
risk, with/without previous RRSO, ascertained through specialist
familial cancer/genetic clinics and BRCA support groups.
Methods Participants completed a 39-item questionnaire. Baseline
characteristics were described using descriptive statistics. Logistic/
linear regression models analysed the impact of variables on
RRESDO acceptability and health outcomes.
Main outcomes RRESDO acceptability, menopausal sequelae,
satisfaction/regret.
Results In all, 346 of 683 participants underwent risk-reducing
salpingo-oophorectomy (RRSO). Of premenopausal women who
had not undergone RRSO, 69.1% (181/262) found it acceptable to
participate in a research study offering RRESDO. Premenopausal
women concerned about sexual dysfunction were more likely to
find RRESDO acceptable (odds ratio [OR] = 2.9, 95% CI 1.2–7.7,
P = 0.025). Women experiencing sexual dysfunction after
premenopausal RRSO were more likely to find RRESDO
acceptable in retrospect (OR = 5.3, 95% CI 1.2–27.5, P < 0.031).
In all, 88.8% (143/161) premenopausal and 95.2% (80/84)
postmenopausal women who underwent RRSO, respectively, were
satisfied with their decision, whereas 9.4% (15/160)
premenopausal and 1.2% (1/81) postmenopausal women who
underwent RRSO regretted their decision. HRT uptake in
premenopausal individuals without breast cancer (BC) was 74.1%
(80/108). HRT use did not significantly affect satisfaction/regret
levels but did reduce symptoms of vaginal dryness (OR = 0.4,
95% CI 0.2–0.9, P = 0.025).
Conclusion Data show high RRESDO acceptability, particularly in
women concerned about sexual dysfunction. Although RRSO
satisfaction remains high, regret rates are much higher for
premenopausal women than for postmenopausal women. HRT
use following premenopausal RRSO does not increase satisfaction
but does reduce vaginal dryness.
Keywords Acceptability, BRCA, ovarian cancer, risk-reducing
early salpingectomy with delayed oophorectomy.
Tweetable abstract RRESDO has high acceptability among
premenopausal women at increased ovarian cancer risk,
particularly those concerned about sexual dysfunction.
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Introduction
Ovarian cancer (OC) is the leading cause of death from
gynaecological malignancies in the UK.1 An effective OC-
screening programme/strategy is not currently clinically
available and 10-year survival rates remain poor at ~30%.
Familial cancers are responsible for ~10–20% of OC and
BRCA1/BRCA2 mutations account for most of the known
hereditary OC risk. BRCA1/BRCA2 carriers have a 17–44%
OC risk and 65–72% breast cancer (BC) risk.2–5 RAD51C/
RAD51D/BRIP1 are newer moderate-penetrance OC genes,
with lifetime OC risks ~6–13%.6–10
Risk-reducing salpingo-oophorectomy (RRSO) is the
most effective method of OC prevention. Traditionally,
women at ≥10% lifetime OC risk were deemed high risk
and offered risk-management/surgical prevention. Calls for
redefining the threshold for surgical prevention have sug-
gested a 4–5% lifetime OC risk,11 as the level demonstrat-
ing clinical utility,12,13 thus enabling intermediate-risk
women to access surgical prevention. This includes those
with moderate-penetrance genetic mutations and mutation-
negative women with a strong OC family history. In
BRCA-women, RRSO reduces OC risk by 79–96%.14–18
Although initial data suggested that premenopausal RRSO
reduced primary BC risk by half,16,19,20 recent papers have
questioned this.21,22 In terms of mortality, RRSO reduces
all-cause (HR = 0.40, 95% CI 0.26–0.61), BC-specific
(HR = 0.44, 95% CI 0.26–0.76) and OC-specific
(HR = 0.25, 95% CI 0.08–0.75) mortality.20 However,
RRSO has disadvantages, including major complication
rates of 1.5–5%.14,23 In premenopausal women, RRSO leads
to surgical menopause and infertility. Premature surgical
menopause has potential detrimental health sequelae
including an increased risk of heart disease, osteoporosis,
vasomotor symptoms, neurocognitive decline and sexual
dysfunction, especially in women who do not or are unable
to use hormone-replacement therapy (HRT).24–28 Conse-
quently, some women choose to delay surgery until after
menopause, risking a 6- to 16-year mean period of much
higher risks of, in particular, high-grade serous OC, espe-
cially with BRCA1.
With increasing evidence and acceptability of the central
role of the fallopian tube in the aetiopathogeneisis of
epithelial OC, risk-reducing early salpingectomy and
delayed oophorectomy (RRESDO) has been proposed as a
two-stage surgical alternative to RRSO. RRESDO offers
some level of risk reduction to women who decline/wish to
delay RRSO while conserving ovarian function and avoid-
ing detrimental consequences of premature
menopause.29–31 However, prospective outcome data for
RRESDO are lacking. The precise level of OC risk reduc-
tion and long-term consequences of ovarian function are
unknown. Concerns have been raised regarding the poten-
tial attrition from delayed oophorectomy. Therefore,
RRESDO is currently recommended in the context of a
clinical trial and 80% of UK clinicians support this.32 Trials
are currently underway in the UK (PROTECTOR;
ISRCTN25173360),33 the Netherlands (TUBA;
NCT02321228)34 and USA (WISP, NCT02760849).35
There is a paucity of international data and a lack of UK
data on RRESDO acceptability among high-risk women. A
US survey showed that 34.3% (70/204) BRCA pathogenic-
variant carriers were interested in participating in a study
offering RRESDO.36 A Dutch qualitative study investigating
barriers and facilitators to RRESDO among BRCA-carriers
found seriousness of OC, family history (FH), previous BC,
uncertainty about the effect of and ease of the decision to
undergo RRSO to be barriers.37 The main facilitator was
longer maintenance of ovarian function to delay negative
effects of premature menopause.37
We present data from a multicentre UK survey in
women at increased OC risk, concerning: (1) acceptability
of RRESDO, (2) menopausal sequelae following RRSO and
(3) satisfaction/regret following RRSO.
Methods
Design
The present study was a multicentre, cohort, questionnaire
study (ISRCTN:12310993). Inclusion criteria were: UK
women aged ≥18 years, at increased OC risk either due to
pathogenic variants in an OC gene (BRCA1/BRCA2/
RAD51C/RAD51D/BRIP1) or strong FH of OC or BC +
OC. A strong FH was defined as ≥2 first-degree relatives
with OC in BRCA1/BRCA2-negative or untested women.
Exclusion criteria were: non-UK residents or women with a
personal history of OC. Women with and without previous
RRSO were invited.
Participants
Participants were selected via six NHS specialist familial
cancer or genetic clinics (Manchester/Cambridge/Barts-
London/University-College-London/Guys-London/Dundee)
and a patient support group for BRCA-carriers (BRCA-
Umbrella).
Recruitment
All participants provided written consent after review of a
detailed participant information-sheet (PIS) along with the
option of completing a paper/web-based questionnaire. The
PIS (Appendix S1) provided information on current OC-
prophylactic surgery available on the NHS (RRSO) and the
proposed two-stage surgical alternative (RRESDO), study
aims, logistics of participation and contact details of
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charities/support groups providing further independent
information/support.
The 39-item questionnaire collected socio-demographic,
surgical/menstrual/FH and health consequences of prema-
ture menopause influencing decisions to undergo/delay/
decline premenopausal RRSO (Likert scale) data for all par-
ticipants. Individuals were instructed to complete different
sections of the questionnaire depending on whether they
had undergone RRSO. Questionnaire items for women
who had not undergone RRSO covered: benefits and
limitations of RRESDO impacting acceptability of proce-
dure (Likert scale); putative acceptability of undergoing
RRESDO (‘yes, no, not sure’ options), acceptability of par-
ticipating in a research study offering RRESDO (Likert
scale); anticipated timing of future surgery (Likert scale).
Questionnaire items for women who had undergone RRSO
covered: retrospective acceptability (Likert scale) of under-
going RRESDO had it been available (item only for women
who had undergone premenopausal RRSO); HRT use (‘yes/
no’); menopause sequelae (Likert scale) following RRSO;
satisfaction and regret (Likert scale) following RRSO.
Respondents could recheck all answers and an optional
free-text box was provided for further comments.
Questionnaire development
The 39-item questionnaire (Appendix S2) was developed in
several stages. An initial draft was developed following a lit-
erature review. Each question was systematically discussed
and debated. These were subsequently reviewed by senior
clinicians in the fields of gynaecological precision medicine
and cancer prevention, and gynaecological oncology. The
clinicians gave each item a relevance score from 1 (least
relevant) to 4 (most relevant) based on their knowledge
and experience. They were also asked to identify any addi-
tional questions which they considered important and
might be missing. A second consensus meeting was held to
review responses to the initial questionnaire, delete low-
relevance items and optimise questionnaire length and
facilitate compliance. A second pilot of the survey was
carried out for readability, ease-of-use and layout. These
processes helped ensure content and face optimisation. The
final version was further reviewed/commented on, resulting
in further rationalisation to a 39-item questionnaire. For
questions pertaining to satisfaction/regret with decision
making, the validated five-item decision regret scale38,39
was used as well as two additional items developed by the
panel of clinical experts exploring the impact of familial
wishes on decision making.
Statistical analysis
Descriptive statistics were used for baseline characteristics
as well as satisfaction/regret questions. Multiple logistic
regression was used to model the effect of variables on the
acceptability of undergoing RRESDO (putative acceptability
in premenopausal women who had not undergone OC-pre-
vention surgery; retrospective acceptability of RRESDO in
women who had undergone premenopausal RRSO), accept-
ability of taking part in a research study offering RRESDO
(premenopausal women not having undergone OC-preven-
tion surgery) and effect of HRT uptake on menopausal
sequelae in women who had undergone premenopausal
RRSO. Multiple linear regression was used to model the
effect of menopausal sequelae on satisfaction/regret follow-
ing premenopausal RRSO, and association of HRT use ver-
sus non-use was also explored. Multiple analyses were
adjusted for marital status, ethnicity, education, income,
FH of OC/BC, risk-reducing mastectomy (RRM) and per-
sonal history of BC. Wilcoxon’s rank-sum test and Fisher’s
exact test were using to test the hypothesis about differ-
ences in means and proportions, respectively. Two-sided P-
values are reported for all statistical tests. Statistical analysis
used R version 3.5.1 (Lucent Technologies, Murray Hill,
NJ, USA).
Patient and public involvement (PPI)
The RRESDO study team undertook extensive stakeholder
engagement before study commencement. Groups involved
included healthcare professionals and BRCA support groups.
This was essential to ensure stakeholder management,
increase engagement and awareness and facilitate develop-
ment and delivery of study. These groups provided input to
the Patient Information Sheet and also served as an indepen-
dent point of contact for more information on the study.
Support groups helped increase study awareness through
their websites/newsletters. They will also be involved in dis-
semination of study findings following publication.
Core outcome sets
There are no core outcome sets for surgical prevention at
present.
Results
Between October 2017 and June 2019, 773 individuals
completed the paper/online-questionnaire. Of these, 90
were excluded because they did not meet the eligibility cri-
teria. The remaining 683 individuals were included in the
analysis. Table 1 summarises baseline cohort characteristics.
In all, 337/683 (49.3%) respondents had not undergone
RRSO and 346/683 (50.7%) had. Women who had not
undergone RRSO were significantly younger than women
who had (38.3 versus 51.5 years, P ≤ 0.001).
Table 2 summarises RRESDO acceptability. Among pre-
menopausal women who had not undergone RRSO, the
overall RRESDO acceptability (‘yes’) was 55.3% (145/262)
and the overall unacceptability (‘no’) was 20.2% (53/262);
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24.4% (64/262) were ‘not sure’. When premenopausal
women who had not undergone RRSO were asked whether
they would consider taking part in a research study offering
RRESDO, overall acceptability (those who responded ‘proba-
bly, maybe’) was 69.1% (181/262) and 30.9% (81/262) found
it unacceptable (‘probably not, definitely not’). Table 2 pro-
vides further details. Multiple logistic-regression model out-
puts showing the association of covariates with acceptability
of undergoing RRESDO (‘yes’ versus ‘no’) among pre-
menopausal women who have not undergone RRSO are
given in Table 3. Genetic-mutation type or carrier-status/
FH/knowledge of tubal origin/future OC-prevention surgery
plans/childbearing/ethnicity/education/income did not sta-
tistically significantly affect RRESDO acceptability. However,
premenopausal women who were more concerned about
sexual dysfunction were three times more likely to find
undergoing RRESDO acceptable than were those less con-
cerned about sexual dysfunction (OR = 2.9, 95% CI 1.2–7.6,
P = 0.025). When considering potential benefits, individuals
wanting to delay hot flushes (OR = 5.0, 95% CI 1.2–21.2,
P = 0.025) were five times more likely to find RRESDO
acceptable. When considering acceptability (‘yes’ versus ‘no’)
of potential limitations of RRESDO, women who found the
risks of undergoing two surgeries (OR = 444.1, 95% CI 28–
22815, P ≤ 0.001), interval-monitoring (CA125/USS)
between surgeries (OR = 59.0, 95% CI 4.2–1548.7,
P = 0.006), uncertainty around level of OC risk reduction
with RRES (OR = 14.6, 95% CI 1.9–160.6, P = 0.015), and
Table 1. Baseline characteristics of cohort
No RRSO
n = 337, 49.3%
RRSO
n = 346, 50.7%
P-value
Mean age in years (SD, range) 38.25 (10.23, 19–81) 51.53 (9.56, 26–81) <0.001
Mean parity (SD, range) 1.92 (0.83, 1–6) 2.18 (0.86, 1–7) <0.001
Nulliparous 217/336, 64.6 286/343, 83.4 <0.001
Premenopausal/premenopausal at time of RRSO 262/335, 78.2 164/248, 66.1 0.001
Postmenopausal/postmenopausal at time of RRSO 73/335, 21.8 84/248, 33.9 0.001
Family complete 194/331, 58.6 318/334, 95.2 <0.001
High risk of OC
BRCA1 carrier 157/337, 46.6 162/346, 46.8 1
BRCA2-carrier 171/337, 50.7 161/346, 46.5 0.284
BRCA1- and BRCA2-carrier 5/337, 1.5 7/346, 2.0 0.773
Intermediate risk of OC
RAD51C-carrier 0/337, 0.0 1/346, 0.3
BRIP1-carrier 3/337, 0.9 1/346, 0.3 0.367
BRCA1/BRCA2-negative but strong FH of OC 1/337, 0.3 2/346, 0.6 1
BRCA1/BRCA2 untested but strong FH of OC 1/337, 0.3 3/346, 0.9 0.624
Unsure of genetic test result 4/337, 1.2 6/346, 1.7 0.752
Personal history of BC 77/337, 22.8 160/346, 46.2 <0.001
Personal history of other cancers 6/337, 1.8 9/346, 2.6 0.604
Therapeutic mastectomy 20/337, 5.9 47/346, 13.6 0.001
Risk-reducing mastectomy 70/337, 20.8 143/346, 41.3 <0.001
Breast surgery for benign breast pathology 0/337, 0.0 4/346, 1.2
Cosmetic breast surgery 2/337, 0.6 1/346, 0.3 0.620
Marital status
Single, divorced, separated, widowed 72/332, 21.7 36/341, 10.6 <0.001
Married, cohabiting/living with partner 260/332, 78.3 305/341, 89.4 <0.001
Ethnicity
Caucasian 301/334, 90.1 300/341, 88.0 0.391
Non-caucasian 33/334, 9.9 41/341, 12.0 0.391
Education
PhD, Masters, Bachelor’s degree 199/329, 60.5 141/336, 42.0 <0.001
NVQ4, A-level/NVQ3, NVQ1/NVQ2, GCSE/O-level/CSE, no formal qualification 130/329, 39.5 195/336, 58.0 <0.001
Total household income
≥£30 000 236/325, 72.6 208/312, 66.7 0.121
<£30 000 89/325, 27.4 104/312, 33.3 0.121
BC, breast cancer; FH, family history; OC, ovarian cancer; RRSO, risk-reducing salpingo-oophorectomy.
90/773 participants were excluded because they were at population-level risk of ovarian cancer. 683 participants eligible for analysis.
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developing an interval OC between the two surgeries
(OR = 9.6, 95% CI 1.4–93.7, P = 0.032) as acceptable, were
more likely to find undergoing RRESDO acceptable. The
wide confidence intervals reflect having too few responses
from premenopausal women who have not undergone RRSO
for certain questionnaire items (acceptability of undergoing
two surgeries/interval monitoring/uncertain OC risk reduc-
tion/developing interval OC). Multiple logistic-regression
model outputs showing association of covariates with accept-
ability of undergoing RRESDO (‘not sure’ versus ‘no’) are
given in Table S1. Premenopausal women who had not
undergone RRSO and who responded ‘not sure’ were more
likely than women who responded ‘no’ to find the two-stage
aspect of RRESDO acceptable (OR = 6.7, 95% CI 1.6–34.0,
P = 0.013) and to find interval monitoring (CA125/USS)
between the two surgeries acceptable (OR = 8.9, 95% CI
1.5–71.8, P = 0.025). Lower acceptability of precision of OC
risk reduction following RRES (OR = 0.2, 95% CI 0.1–0.4,
P < 0.0005) was the predominant factor affecting pre-
menopausal women who were ‘not sure’ about undergoing
RRESDO compared with those responding ‘yes’. When asked
about the acceptability of complication rates, 157 (80.1%)
premenopausal women found the complication rate with
two procedures acceptable; 125 (87.4%) women who would
undergo RRESDO found this acceptable versus 32 (60.4%)
women who would not undergo RRESDO.
When women who had undergone premenopausal RRSO
were asked whether they would have considered undergo-
ing RRESDO instead of RRSO had it been offered (retro-
spective acceptability), 38.4% (61/159) and 61.6% (98/159)
responded ‘probably/maybe’ and ‘probably not/definitely
not’, respectively (Table 2). Multiple logistic-regression
model outputs showing association of covariates with ret-
rospective RRESDO acceptability following premenopausal
RRSO are given in Table 4. Genetic-mutation type or car-
rier-status/FH/prior knowledge of tubal origin of OC/eth-
nicity/education/income did not statistically significantly
affect retrospective acceptability of undergoing RRESDO.
Following premenopausal RRSO, women who experienced
night sweats (OR = 13.8, 95% CI 1.7–140.2, P = 0.018),
sleep disturbance (OR = 18.8, 95% CI 3.2–160.1,
P = 0.003), sexual dysfunction (OR = 5.3, 95% CI 1.2–
27.5, P = 0.031) or urinary incontinence (OR = 17.2, 95%
CI 4–98.6, P < 0.001) regretted their decision to undergo
RRSO (OR = 6.4, 95% CI 1.3–40.7, P = 0.032); they also
felt the decision to undergo RRSO did them a lot of harm
(OR = 3.9, 95% CI 1.2–12.8, P = 0.022) and were statisti-
cally significantly more likely to have chosen retrospectively
to undergo RRESDO instead of RRSO had it been avail-
able. However, women who experienced hot flushes (OR =
0.1, 95% CI 0–0.6, P = 0.013), osteoporosis (OR = 0.3,
95% CI 0.1–0.9, P = 0.045) or fatigue (OR = 0.01, 95% CI
0–0.1, P < 0.001) following premenopausal RRSO were
statistically significantly less likely to have chosen to have
undergone RRESDO instead of RRSO retrospectively.
Overall, HRT use among premenopausal women post-
RRSO was 53.7% (88/164). However, when stratified by BC
status at the time of premenopausal RRSO, the HRT
uptake was 74.1% (80/108) among BC-unaffected and
14.3% (8/56) among BC-affected individuals. The mean age
at premenopausal RRSO was 47.2 (SD = 6.7) years and the
mean duration of HRT use was 4.2 (SD = 3) years. No
woman who had undergone postmenopausal RRSO used
HRT. The multiple logistic-regression model explored the
association of covariates with HRT use versus non-use fol-
lowing premenopausal RRSO. Women with a university
level (versus below university) education (OR = 3.1, 95%
CI 1.2–8.5, P = 0.021) and women who were aware/con-
cerned about neurocognitive decline (OR = 11.2, 95% CI
1.2–136.8, P = 0.045) were significantly more likely to use
HRT. There was no difference in HRT use versus non-use
in women who had undergone premenopausal RRSO who
were experiencing sexual dysfunction.
Table S2 reports satisfaction/regret with the RRSO deci-
sion making by menopausal status at the time of surgery.
There was high satisfaction (‘agree/strongly agree’ responses)
among women who had undergone premenopausal and
postmenopausal RRSO (88.82% [143/161] and 95.24% [80/
84], respectively, P = 0.635) and a similarly high proportion
would make the same decision again (87.6% [141/161] ver-
sus 94% [79/84], P = 0.186). When compared with women
undergoing postmenopausal RRSO, those undergoing
Table 2. RRESDO acceptability
Acceptability n (%)
Acceptability of undergoing RRESDO among premenopausal
women who have not undergone RRSO
Yes 145/262 (55.34)
No 53/262 (20.23)
Not sure 64/262 (24.43)
Acceptability of participating in a research study offering
RRESDO among premenopausal women who have not
undergone RRSO
Probably 95/262 (36.26)
Maybe 86/262 (32.82)
Probably not 48/262 (18.32)
Definitely not 33/262 (12.60)
Retrospective acceptability of RRESDO among women who
have undergone premenopausal RRSO
Probably 28/159 (17.61)
Maybe 33/159 (20.75)
Probably not 46/159 (28.93)
Definitely not 52/159 (32.70)
RRESDO, risk-reducing early salpingectomy with delayed
oophorectomy; RRSO, risk-reducing salpingo-oophorectomy.
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premenopausal RRSO had a statistically significantly higher
regret rate (respectively 9.4% [15/160] versus 1.2% [1/81],
P = 0.008) and were more likely to feel that RRSO did them
a lot of harm (11.25% [18/160] versus 5% [4/80],
P = 0.006). Multiple linear-regression modelling showed
that HRT use did not statistically significantly affect satisfac-
tion/regret levels in premenopausal women. Correlation
analysis did not find a statistically significant association
between satisfaction/regret and age of premenopausal RRSO
(r = 0.085, P = 0.292). Multiple linear-regression model
outputs showing an association of menopausal sequelae with
satisfaction/regret following premenopausal RRSO are given
in Table S3. Women experiencing menopausal sequelae (sex-
ual dysfunction, night sweats, sleep disturbance, vaginal dry-
ness, urinary incontinence, fatigue, memory loss, mood
alterations, negative impact on relationship with partner)
were significantly more likely to regret undergoing pre-
menopausal RRSO. The multiple logistic-regression model
explored the association of HRT use with non-use on meno-
pausal sequelae after premenopausal RRSO (Table S4). HRT
users (compared with non-users) were significantly less likely
to experience vaginal dryness (OR = 0.4, 95% CI 0.2–0.9,
P = 0.025) but the prevalence of other symptoms was not
reduced.
Table 3. Factors affecting acceptability of undergoing RRESDO among premenopausal women who have not undergone RRSO
OR SE P > |z| 95% CI
Prior knowledge of tubal origin of OC 1.725 0.376 0.147 0.833–3.655
Personal history of BC 1.184 0.558 0.761 0.404–3.672
Previous RRM 0.647 0.407 0.285 0.286–1.421
Family complete 1.146 0.516 0.792 0.417–3.214
Carrier status 1.788 0.911 0.523 0.273–10.928
Marital status 0.679 0.425 0.362 0.289–1.545
Ethnicity 0.492 0.599 0.237 0.153–1.66
Education 0.876 0.408 0.747 0.388–1.94
Income 1.053 0.177 0.77 0.742–1.492
Timing of future OC prevention surgery 0.286 1.171 0.286 0.014–2.095
Family history
BC 2.889 0.63 0.093 0.813–9.999
OC 1.019 0.785 0.98 0.214–4.799
BC and OC 0.869 0.867 0.871 0.158–4.835
Concerns over premature menopause sequelae influencing decision to undergo RRESDO
Hot flushes/night sweats 1.27 0.502 0.634 0.475–3.451
Looking older 0.804 0.5 0.663 0.295–2.131
Decreased libido/other sexual side effects 2.918 0.477 0.025 1.163–7.648
Loss of fertility 1.568 0.608 0.459 0.468–5.208
Osteoporosis 1.931 0.567 0.246 0.628–5.895
Heart disease 0.845 0.625 0.787 0.239–2.832
Dementia/memory dysfunction 2.435 0.67 0.184 0.67–9.495
Impact on survival 0.488 0.511 0.16 0.17–1.281
Acceptability of having to take HRT until 51 years 1.501 0.437 0.353 0.64–3.586
Potential benefits of RRESDO influencing decision to undergo RRESDO
Reduces risk of OC without premature menopause 9.007 1.195 0.066 1.149–192.856
Inspection of tubes/ovaries by doctor 2.323 0.798 0.291 0.474–11.476
delays hot flushes, night sweats 5.028 0.719 0.025 1.218–21.172
delays osteoporosis 1.08 1.332 0.954 0.083–17.385
delays potential change to sexual function 2.945 0.735 0.142 0.682–12.753
Not associated with increased risk of heart disease 1.279 1.127 0.827 0.114–11.238
Potential limitations of RRESDO influencing decision to undergo RRESDO
Two staged surgery 444.078 1.672 <0.001 *28.04– 22814.9
Potential premature menopause 1.939 0.888 0.456 0.348–12.145
Increased complication rate 0.78 1.014 0.807 0.091–5.333
Interval monitoring between surgeries 59.027 1.471 0.006 4.221–1548.671*
Additional time in hospital 0.028 1.94 0.065 0–1.081
Additional time off work for surgery/post-operative recovery 6.166 1.453 0.21 0.406–139.284
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Table S5 reports the prevalence of menopausal sequelae
following pre- and postmenopausal RRSO. The prevalence
of sequelae in premenopausal women ranged from 50 to
74.1%, with 66.3% of women experiencing sexual dysfunc-
tion and 66.9–74.1% experiencing hot flushes/night sweats/
sleep disturbance. Symptoms were significantly more fre-
quent following premenopausal than following menopausal
RRSO (Table S5).
Discussion
Main findings
Putative acceptability of undergoing RRESDO among pre-
menopausal women who have not undergone OC prevention
surgery is 55.3%, and 69.1% would find participating in a
research study offering RRESDO acceptable. Premenopausal
women who have not undergone OC-prevention surgery and
were concerned about/wanted to delay sexual dysfunction
were statistically significantly more likely to find undergoing
RRESDO acceptable and participate in a research study offer-
ing RRESDO. Similarly, women who had undergone pre-
menopausal RRSO and experienced sexual dysfunction/
vasomotor symptoms/urinary incontinence were signifi-
cantly more likely to regret their decision and find RRESDO
acceptable retrospectively. In all, 38.4% of women who
underwent premenopausal RRSO would retrospectively have
found RRESDO acceptable were it an option. Although satis-
faction with undergoing RRSO was high (premenopausal
RRSO = 88.82%, postmenopausal RRSO = 95.24%) for
women undergoing premenopausal RRSO, 9.38% regretted
their decision and 11.25% felt it did them a lot of harm. Our
data suggest good HRT compliance, with 74% of BC-unaf-
fected women using HRT until the recommended age of 51.
HRT use did not statistically significantly affect satisfaction/
regret levels or alleviate menopausal symptoms except vagi-
nal dryness among women undergoing premenopausal
RRSO. There was a higher prevalence of menopausal seque-
lae following premenopausal RRSO. Women who experi-
enced menopausal sequelae following premenopausal RRSO
had higher regret levels.
Strengths and weaknesses
Strengths include that participants were informed in detail
about OC-prevention surgery with a detailed participant
information-sheet prior to completing our questionnaire;
ours is the only study to have generated UK data on
RRESDO acceptability and menopausal sequelae/satisfac-
tion/regret following RRSO and it is the largest study inter-
nationally reporting RRESDO acceptability. Limitations
include that the proportions of individuals with a
Table 3. (Continued)
OR SE P > |z| 95% CI
Precise level of OC risk reduction with ES unknown 14.556 1.095 0.015 1.961–160.637
Developing an interval OC between the two surgeries 9.554 1.05 0.032 1.405–93.72
BC, breast cancer; FH, family history; HRT, hormone replacement therapy; OC, ovarian cancer; RRESDO, risk-reducing early salpingectomy with
delayed oophorectomy; RRM, risk-reducing mastectomy.
Multiple logistic regression analysis on factors affecting acceptability of undergoing RRESDO (‘yes’ versus ‘no’ responses) in 198 premenopausal
women who have not undergone RRSO. Model adjusted for marital status, ethnicity, education, income, family history of ovarian cancer/breast
cancer, risk-reducing mastectomy and personal history of breast cancer.
Prior knowledge of tubal origin of OC: ‘yes’ versus ‘no’; personal history of BC: ‘yes’ versus ‘no’; previous RRM: ‘yes’ versus ‘no’; family complete:
‘no’ versus ‘yes’; carrier status: BRCA1/BRCA2 versus intermediate risk (RAD51C carrier/RAD51D carrier/BRIP1 carrier/BRCA negative but strong FH
of OC/BRCA untested but strong FH of OC); marital status: in a relationship (married, cohabiting/living with partner) versus not in a relationship
(single, divorced, separated, widowed); ethnicity: non-caucasian versus caucasian; education: university level education (PhD, Masters, Bachelor’s
degree) versus below university level education (NVQ4, A-level/NVQ3, NVQ1/NVQ2, GCSE/O-level/CSE, no formal qualification); timing of future
OC prevention surgery: planning surgery now/within 5 years versus not planning surgery; FH BC (FH of BC alone plus FH of BC and OC): ‘yes’
versus ‘no’; FH OC (FH of OC alone plus FH of OC and BC): ‘yes’ versus ‘no’; FH BC and OC: ‘yes’ versus ‘no’; hot flushes/night sweats: ‘yes’
versus ‘no’; looking older: ‘yes’ versus ‘no’; decreased libido/other sexual side effects: ‘yes’ versus ‘no’; loss of fertility: ‘yes’ versus ‘no’;
osteoporosis (self-reported): ‘yes’ versus ‘no’; heart disease: ‘yes’ versus ‘no’; dementia/memory dysfunction: ‘yes’ versus ‘no’; impact on survival:
‘yes’ versus ‘no’; acceptability of having to take HRT until 51 years: ‘yes’ versus ‘no’; reduces risk of OC without premature menopause: ‘yes’
versus ‘no’; inspection of tubes/ovaries by doctor: ‘yes’ versus ‘no’; delays hot flushes/night sweats: ‘yes’ versus ‘no’; delays osteoporosis: ‘yes’
versus ‘no’; delays potential change to sexual function: ‘yes’ versus ‘no’; not associated with increased risk of heart disease: ‘yes’ versus ‘no’;
two-stage surgery: ‘yes’ versus ‘no’; potential premature menopause: ‘yes’ versus ‘no’; increased complication rate: ‘yes’ versus ‘no’; interval
monitoring between surgeries: ‘yes’ versus ‘no’; additional time in hospital: ‘yes’ versus ‘no’; additional time off work for surgery/postoperative
recovery: ‘yes’ versus ‘no’; precise level of OC risk reduction with ES unknown: ‘yes’ versus ‘no’; developing an interval OC between the two
surgeries: ‘yes’ versus ‘no’.
*Extreme value of some upper limits of confidence intervals indicate that there were too few responses in some categories of responses.
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university degree/household income of ≥UK£ 30,000 were
higher than the UK national average and 88% of our
cohort were caucasian. Consequently, these results may not
be generalisable to a minority, lesser educated/affluent
population of BRCA-carriers. Also, because only 1.77%
(12/683) of our cohort were at intermediate OC risk, no
inferences can be drawn for this subgroup. In addition,
questionnaire responses may have been affected by recall
Table 4. Factors associated with retrospective acceptability of RRESDO among women who have undergone premenopausal RRSO
OR SE P > |z| 95% CI
Prior knowledge of tubal origin of ovarian cancer 1.514 0.444 0.35 0.63–3.625
Personal history of breast cancer 0.731 0.468 0.504 0.289–1.824
Previous risk reducing mastectomy 0.618 0.456 0.291 0.249–1.5
Carrier status 1.626 0.898 0.589 0.31–12.385
Marital status 0.716 0.458 0.466 0.291–1.768
Ethnicity 1.184 0.635 0.791 0.321–4.058
Education 1.11 0.398 0.793 0.507–2.433
Income 1.079 0.194 0.695 0.739–1.589
FH
BC 1.445 0.896 0.682 0.281–11.041
OC 1.754 1.120 0.616 0.198–18.561
BC and OC 0.944 1.166 0.961 0.083–9.194
Experienced menopausal sequelae following RRSO
Hot flushes 0.09 0.955 0.013 0.013–0.566
Night sweats 13.76 1.108 0.018 1.729–140.177
Sleep disturbance 18.78 0.988 0.003 3.186–160.144
Vaginal dryness 0.76 0.658 0.671 0.204–2.774
Sexual dysfunction 5.34 0.779 0.031 1.244–27.467
Loss of fertility 0.70 0.669 0.587 0.174–2.501
Osteoporosis 0.25 0.700 0.045 0.057–0.919
Urinary incontinence 17.20 0.807 <0.001 3.985–98.597
Fatigue 0.01 1.150 <0.001 0.001–0.096
Memory loss 0.67 0.662 0.541 0.177–2.45
Mood alterations 3.06 0.684 0.102 0.834–12.654
Impact on relationship with partner 1.81 0.676 0.379 0.49–7.158
Satisfaction/regret following RRSO
I regret the choice that was made 6.385 0.866 0.032 1.251–40.746
I would make the same decision if I had to do it over again 0.471 4.597 0.87 0.001–205.952
The decision did me a lot of harm 3.877 0.590 0.022 1.226–12.795
I was directly influenced by the direct wishes of my family 3.762 0.700 0.058 0.974–15.615
I was influenced by the unexpressed wishes of my family 0.401 0.734 0.212 0.089–1.631
BC, breast cancer; FH, family history; HRT, hormone replacement therapy; OC, ovarian cancer; RRESDO, risk-reducing early salpingectomy with
delayed oophorectomy; RRM, risk-reducing mastectomy.
Multiple logistic regression analysis on factors affecting retrospective acceptability (‘probably, maybe’ versus ‘probably not, definitely not’
responses) of undergoing RRESDO had it been an option in 159 women who have undergone premenopausal RRSO. Model adjusted for marital
status, ethnicity, education, income, family history of ovarian cancer/breast cancer, risk-reducing mastectomy and personal history of breast
cancer. Prior knowledge of tubal origin of OC: ‘yes’ versus ‘no’; personal history of BC: ‘yes’ versus ‘no’; previous RRM: ‘yes’ versus ‘no’; family
complete: no versus yes; carrier status: BRCA1/BRCA2 versus intermediate risk (RAD51C carrier/RAD51D carrier/BRIP1 carrier/BRCA-negative but
strong FH of OC/BRCA untested but strong FH of OC); marital status: in a relationship (married, cohabiting/living with partner) versus not in a
relationship (single, divorced, separated, widowed); ethnicity: non-caucasian versus caucasian; education: university level education (PhD, Masters,
Bachelor’s degree) versus below university level education (NVQ4, A-level/NVQ3, NVQ1/NVQ2, GCSE/O-level/CSE, no formal qualification); timing
of future OC prevention surgery: planning surgery now/within 5 years versus not planning surgery; FH BC (FH of BC alone plus FH of BC and
OC): ‘yes’ versus ‘no’; FH OC (FH of OC alone plus FH of OC and BC): ‘yes’ versus ‘no’; FH BC and OC: ‘yes’ versus ‘no’; hot flushes: ‘yes’ versus
‘no’; night sweats: ‘yes’ versus ‘no’; sleep disturbance: ‘yes’ versus ‘no’; vaginal dryness: ‘yes’ versus ‘no’; sexual dysfunction: ‘yes’ versus ‘no’;
loss of fertility: ‘yes’ versus ‘no’; osteoporosis (self-reported): ‘yes’ versus ‘no’; urinary incontinence: ‘yes’ versus ‘no’; fatigue: ‘yes’ versus ‘no’;
memory loss: ‘yes’ versus ‘no’; mood alterations: ‘yes’ versus ‘no’; impact of relationship with partner: ‘yes’ versus ‘no’; it was the right decision:
‘yes’ versus ‘no’; I regret the choice that was made: ‘yes’ versus ‘no’; I would make the same decision if I had to do it over again: ‘yes’ versus
‘no’; the decision did me a lot of harm: ‘yes’ versus ‘no’; the decision was a wise one: ‘yes’ versus ‘no’; I was directly influenced by the direct
wishes of my family: ‘yes’ versus ‘no’; I was influenced by the unexpressed wishes of my family: ‘yes’ versus ‘no’.
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bias. We excluded women with a previous history of OC
so as not to bias results, as they do not reflect unaffected
women considering prophylactic OC-surgery.
Interpretation
A US survey-study reported 34.3% (70/204) acceptability in
taking part in a research study offering RRESDO among
premenopausal women who had not undergone RRSO.36
This is lower than the 69.1% (181/262) we found, despite
both cohorts being similar in terms of baseline demograph-
ics (mean age 38.25 versus 35.4 years; 88 versus 90.7% cau-
casian, personal history of BC 22.8 versus 16.7%) and our
cohort having more nulliparous women (64.6 versus
41.2%). Differences in healthcare systems (UK state-funded
versus US-privatised/insurance-based) and increasing
awareness may have contributed to the dissimilar findings.
In the USA, 32.8% (20/61) of women not interested in par-
ticipating in a research study offering RRESDO, cited con-
cerns related to additional healthcare costs as their reason
to decline participation.36
The lack of a precise level of OC risk-reduction data
with ES was an important limitation for premenopausal
women who had not undergone OC-prophylactic surgery
and who did not find RRESDO acceptable. Additionally,
impaired sexual function, as a direct consequence of pre-
menopausal-oophorectomy, is an extremely important con-
sideration for women who have not undergone surgical
prevention. There are currently three trials open to recruit-
ment, investigating aspects of RRESDO.40 The UK trial
PROTECTOR33 and US trial WISP35 are both powered on
sexual function and will provide valuable information on
the impact of RRESDO on sexual function. That women
experiencing night sweats/urinary incontinence/sexual dys-
function were significantly more likely to find RRESDO
acceptable but those experiencing other symptoms might
not, suggests there is a range of tolerability and acceptabil-
ity of various symptoms among women which affects surgi-
cal decision making.
Our data show 50.7% (346/683) RRSO uptake, which is
consistent with literature reports of 12–78%.14,24,27,36,41–68
Uptake was higher among older women, women who com-
pleted childbearing, those who had BC themselves, and
those having undergone RRM. This is in keeping with pub-
lished data.41,44,47,50,57,62,69,70
Offering RRESDO to premenopausal women who have
completed childbearing may reduce uptake of pre-
menopausal RRSO. This is supported by our data, which
show that 38.4% of women who had undergone pre-
menopausal RRSO would have in retrospect found
RRESDO acceptable had it been an option. However,
RRESDO may increase the overall number of women
undergoing premenopausal OC surgical prevention, as it
offers an alternative option to individuals otherwise
declining premenopausal oophorectomy due to the negative
consequences of premature menopause.
Satisfaction following RRSO in BRCA-carriers is reported
to be high at 86–97% at 1-3 years post-surgery,27,46,66,71,72
which is in keeping with our results. However, 9.4% (15/
150) women in our cohort who underwent premenopausal
RRSO regretted their decision, which is higher than the 5–
7% reported 2–3 years post-RRSO in the literature.27,71
Our data show a positive correlation between regret and
menopausal sequelae following surgery. However, these
results must be interpreted with caution in light of the
small number of women (n = 15) who reported regret.
There are no published data on the effect of HRT on satis-
faction/regret following RRSO. Our results show that HRT
use did not statistically significantly affect satisfaction/regret
levels in women who had undergone premenopausal RRSO
despite a high HRT uptake of 74.1% in BC-unaffected
women who have undergone premenopausal RRSO. HRT
uptake in women undergoing premenopausal RRSO is
reported to be 8–75% in the literature.28,72–75 Although our
reported uptake is at the upper end of this range, it may
not be a true reflection of practice in the UK. We acquired
our data through specialist familial cancer clinics which
manage women in a multidisciplinary setting that includes
routine counselling on the detrimental health sequelae of
premature menopause along with the importance of HRT
in mitigating these risks and input/access to menopause
specialists for symptom and sequelae management. A large
proportion of UK women at increased OC risk are man-
aged in non-specialist settings and may receive inconsistent
menopause management advice.76 Short-term HRT use fol-
lowing premenopausal RRSO in unaffected BRCA1/BRCA2-
carriers is beneficial.77–80 Premenopausal women should be
involved in formulating an individualised pre-surgical
menopause symptom management and HRT-plan and fully
counselled regarding the consequences of iatrogenic meno-
pause, treatment benefits and its efficacy in alleviating vaso-
motor symptoms and sexual dysfunction. This needs to be
discussed as part of informed consent and incorporated
into the RRSO decision-making process.
Contrary to our data, the literature shows that HRT use
following premenopausal RRSO reduces the prevalence and
severity of hot flushes.28,75,81,82 However, consistent with
our data, according to the literature, HRT use following
premenopausal RRSO reduces vaginal dryness but does not
alleviate sexual dysfunction (sexual pleasure/habit/satisfac-
tion/libido).28,72,75,81
The literature reports that women undergoing pre-
menopausal RRSO experience a significant worsening of
endocrine symptoms (hot flushes/night sweats/sweating).72
However, the literature on endocrine symptoms following
postmenopausal RRSO is conflicting with different studies
reporting either no increase72 or increase in the prevalence
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of endocrine symptoms.27 In our study, baseline levels of
menopausal sequelae symptoms prior to premenopausal
and postmenopausal RRSO were not recorded, and
although our data show a prevalence of 66.9–74.1% and
25.4–40.7% of endocrine symptoms following pre- and
postmenopausal RRSO, respectively, we cannot be certain
some symptoms were not already present prior to RRSO or
whether they worsened following surgery, particularly in
postmenopausal women.
Conclusion
Acceptance of the central role of the fallopian tube in
aetiopathogenesis of OC and health consequences of prema-
ture menopause from oophorectomy has led to RRESDO
being proposed as a surgical alternative for premenopausal
women whose family is complete but who decline/delay
oophorectomy. Given lack of data on long-term health, the
extent of OC risk reduction and concerns over attrition,
RRESDO is currently recommended only within the context
of a research trial. A total of 69.1% of UK women who have
not undergone premenopausal oophorectomy and particu-
larly women concerned about sexual dysfunction would find
it acceptable to participate in a research study offering
RRESDO. Although RRSO remains the gold standard for OC
prevention, ~10% who undergo premenopausal RRSO regret
their decision, particularly due to menopausal sequelae. HRT
uptake is good in women managed in specialist centres.
Although HRT use has been shown to mitigate some endo-
crine symptoms, it does not appear to alleviate sexual dys-
function or increase satisfaction levels following RRSO.
Women at increased OC risk contemplating OC-prevention
surgery may be better managed in a multidisciplinary setting
of specialist familial cancer clinics with input from gynaecol-
ogists/psychologists/menopause/fertility specialists with links
to genetics teams.
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